Vertex Pharmaceuticals Incorporated (VRTX) reported fourth-quarter 2025 results. Total revenue was $3.19 billion, up 9.55% year over year, versus the consensus revenue estimate of $3.24 billion.
Cash flow and balance-sheet highlights showed stronger liquidity and activity.
Cost of goods sold stood at $466 million (+10.06% YoY). After the release, the stock was down 1.94% since market close.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Vertex Pharmaceuticals Incorporated Insider Trading Activity
Vertex Pharmaceuticals Incorporated insiders have traded $VRTX stock on the open market 26 times in the past 6 months. Of those trades, 0 have been purchases and 26 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by insiders over the last 6 months:
- JEFFREY M LEIDEN (Executive Chairman) has made 0 purchases and 17 sales selling 137,073 shares for an estimated $60,942,656.
- CHARLES F JR WAGNER (EVP, CO & FO) has made 0 purchases and 3 sales selling 23,532 shares for an estimated $10,778,252.
- OURANIA TATSIS (EVP, Chief Reg. & Quality Off.) has made 0 purchases and 2 sales selling 9,000 shares for an estimated $4,162,410.
- EDWARD MORROW III ATKINSON (EVP, Chief Technical Ops. Off.) sold 2,500 shares for an estimated $1,086,450
- JONATHAN BILLER (EVP and Chief Legal Officer) has made 0 purchases and 2 sales selling 1,041 shares for an estimated $436,324.
- SANGEETA N. BHATIA sold 266 shares for an estimated $102,859
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Vertex Pharmaceuticals Incorporated Hedge Fund Activity
We have seen 792 institutional investors add shares of Vertex Pharmaceuticals Incorporated stock to their portfolio, and 737 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 3,102,604 shares (-48.4%) from their portfolio in Q3 2025, for an estimated $1,215,103,830
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 2,706,761 shares (+88.2%) to their portfolio in Q3 2025, for an estimated $1,060,075,878
- PARNASSUS INVESTMENTS, LLC removed 1,648,433 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $747,333,584
- BLACKROCK, INC. added 1,498,942 shares (+6.7%) to their portfolio in Q4 2025, for an estimated $679,560,345
- WINSLOW CAPITAL MANAGEMENT, LLC added 887,640 shares (+inf%) to their portfolio in Q4 2025, for an estimated $402,420,470
- CAPITAL RESEARCH GLOBAL INVESTORS added 763,063 shares (+4.6%) to their portfolio in Q4 2025, for an estimated $345,942,241
- ARTISAN PARTNERS LIMITED PARTNERSHIP removed 650,259 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $254,667,434
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Vertex Pharmaceuticals Incorporated Congressional Stock Trading
Members of Congress have traded $VRTX stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by members of Congress over the last 6 months:
- REPRESENTATIVE DAVID TAYLOR sold up to $15,000 on 01/29.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Vertex Pharmaceuticals Incorporated Analyst Ratings
Wall Street analysts have issued reports on $VRTX in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Bernstein issued a "Outperform" rating on 01/12/2026
- Leerink Partners issued a "Outperform" rating on 12/29/2025
- Wells Fargo issued a "Overweight" rating on 12/10/2025
- UBS issued a "Buy" rating on 11/07/2025
- Citigroup issued a "Buy" rating on 10/02/2025
- Evercore ISI Group issued a "Outperform" rating on 09/11/2025
To track analyst ratings and price targets for Vertex Pharmaceuticals Incorporated, check out Quiver Quantitative's $VRTX forecast page.
Vertex Pharmaceuticals Incorporated Price Targets
Multiple analysts have issued price targets for $VRTX recently. We have seen 13 analysts offer price targets for $VRTX in the last 6 months, with a median target of $545.0.
Here are some recent targets:
- Eliana Merle from Barclays set a target price of $606.0 on 01/28/2026
- Michael Yee from UBS set a target price of $545.0 on 01/26/2026
- Liisa Bayko from Evercore ISI Group set a target price of $530.0 on 01/23/2026
- Brian Abrahams from RBC Capital set a target price of $546.0 on 01/22/2026
- Andy Chen from Wolfe Research set a target price of $548.0 on 01/06/2026
- David Risinger from Leerink Partners set a target price of $525.0 on 12/29/2025
- Mohit Bansal from Wells Fargo set a target price of $515.0 on 12/10/2025
